Kadcyla 160 mg (Trastuzumab emtansine 160 mg) by Roche.
Indications: HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy; HER2-positive metastatic breast cancer.
Administration: Intravenous infusion of 3.6 mg/kg every 3 weeks.
Storage: Store in a refrigerator at 2–8 °C. Do not freeze. Keep in the outer carton to protect from light.
Prescription-only medicine (POM). Supplied against a valid prescription / to licensed healthcare professionals only.
| Manufacturer | Roche |
| Active ingredient | Trastuzumab emtansine 160 mg — HER2-targeted antibody–drug conjugate. |
| Strength & pack | 1 single-use vial. |
| Form | Powder for concentrate for solution for infusion |
| Storage | Store in a refrigerator at 2–8 °C. Do not freeze. Keep in the outer carton to protect from light. |
| Regulatory status | Prescription-only medicine (POM). Supplied against a valid prescription / to licensed healthcare professionals only. |